Sleep tech's central 2026 debate is whether GLP-1 drugs like Eli Lilly's Zepbound (now FDA-approved for sleep apnea) shrink ResMed's addressable market or expand it by driving more patients into diagnosis — a question sharp enough to trigger a Morgan Stanley downgrade and then a multi-month stock recovery within the same year, even as the underlying category remains only 5% penetrated in the US.
📈 What changed: Morgan Stanley downgraded ResMed, citing concerns that GLP-1 weight-loss drugs and Philips' return to the US PAP market could pressure margins and growth.
| Indicator | Score | Reading |
|---|---|---|
| Maturity higher is better · high confidence | 82/100 | A scaled, deeply under-penetrated category now facing a genuine structural question: do GLP-1 weight-loss drugs shrink or grow the sleep-apnea funnel? |
| Evidence Strength higher is better · high confidence | 75/100 | SEC filings and sell-side coverage of both incumbents provide strong, well-corroborated evidence, including of the GLP-1 competitive narrative itself. |
| Commercial Proximity higher is better · high confidence | 71/100 | Real, cash-generative recurring revenue at ResMed's scale, though Inspire's growth has decelerated sharply amid GLP-1 competitive concerns. |
| Capital & Policy Support higher is better · medium confidence | 31/100 | CMS reimbursement changes and Philips Respironics' still-active FDA consent decree — which continues to bar it from selling new CPAP/BiPAP devices in the US — matter more than any coordinated national strategy. |
| Crowding Risk lower is better · medium confidence | 50/100 | Sentiment has swung sharply on the GLP-1 narrative — recently recovering after a period of genuine de-rating. |
| Reflexivity Risk lower is better · high confidence | 54/100 | The GLP-1 narrative has proven to be the single biggest swing factor in this category's sentiment over the past year. |
Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.
The public page is the summary (backed by 8 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.
Open in the appStart free →The Northstar Signal — what moved across all 350 themes and why, in your inbox. Free, no spam, one-click unsubscribe.